Open Access<p>Design, Synthesis and Biological Evaluation of New HDAC1 and HDAC2 Inhibitors Endowed with Ligustrazine as a Novel Cap Moiety</p>
Author(s) -
Mohammad M. Al-Sanea,
Lizaveta Gotina,
Mamdouh F. A. Mohamed,
Della Grace Thomas Parambi,
Hesham A.M. Gomaa,
Bijo Mathew,
Bahaa G.M. Youssif,
Khalid Saad Alharbi,
Zainab M. Elsayed,
Mohamed A. Abdelgawad,
Wagdy M. Eldehna
Publication year - 2020
Publication title -
drug design, development and therapy
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.964
H-Index - 64
ISSN - 1177-8881
DOI - 10.2147/dddt.s237957
Subject(s) - hdac1 , protein data bank (rcsb pdb) , ic50 , chemistry , histone deacetylase 2 , moiety , docking (animal) , histone deacetylase , histone h3 , stereochemistry , gefitinib , biochemistry , pharmacology , in vitro , histone , biology , receptor , epidermal growth factor receptor , medicine , nursing , gene
Histone deacetylases (HDACs) represent one of the most validated cancer targets. The inhibition of HDACs has been proven to be a successful strategy for the development of novel anticancer candidates.